Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection

SUMMARY: Retrospective analysis of the post–propensity score (PS)–matched cohort of 8426 outpatients balanced in clinical and demographic covariates showed that treatment with casirivimab-imdevimab monoclonal antibody was effective against the SARS-CoV-2 Delta variant to reduce hospitalization, mort...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Obaidi, Mohanad M, Gungor, Ahmet B, Nematollahi, Saman, Zangeneh, Tirdad T, Bedrick, Edward J, Johnson, Katherine M, Low-Adegbija, Nicole E, Alam, Ruhaniyah, Rangan, Pooja, William Heise, C, Ariyamuthu, Venkatesh K, Shetty, Aneesha, Qannus, Abd Assalam, Murugapandian, Sangeetha, Ayvaci, Mehmet M S, Anand, Prince Mohan, Tanriover, Bekir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047202/
https://www.ncbi.nlm.nih.gov/pubmed/35791354
http://dx.doi.org/10.1093/ofid/ofac186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047202/
https://www.ncbi.nlm.nih.gov/pubmed/35791354
http://dx.doi.org/10.1093/ofid/ofac186

Ejemplares similares